Racial and Ethnic Disparities in COVID-19 Treatments in the United States
Essy Mozaffari(Gilead Sciences (United States)), Chidinma Chima-Melton, Vishnudas Sarda, André C. Kalil(Nebraska Medical Center), Aastha Chandak(University of Nebraska Medical Center), Gina Brown(Imperial College Healthcare NHS Trust), Jason F. Okulicz(Gilead Sciences (United States)), Robert Gottlieb(Baylor University Medical Center), Mark Berry(Gilead Sciences (United States)), Alpesh Amin(University of California, Irvine)
Cited by 7
Related Papers
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis
|JAMA|2013|797
Influenza virus-related critical illness: pathophysiology and epidemiology
|Critical Care|2019|509
Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral Therapy
|New England Journal of Medicine|2013|358
Clinical Outcomes of Elite Controllers, Viremic Controllers, and Long‐Term Nonprogressors in the US Department of Defense HIV Natural History Study
|The Journal of Infectious Diseases|2009|305
Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*
|Critical Care Medicine|2003|302